Nicotine and inflammatory neurological disorders

Acta Pharmacologica Sinica

Volumn 30, Issue 6, 2009, Pages 715-722

  Piao, Wen Hua ^a,b   Campagnolo, Denise ^a   Dayao, Carlos ^a   Lukas, Ronald J ^a   Wu, Jie ^a   Shi, Fu Dong ^a  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

^b Ningxia People's Hospital   (China)

Author keywords

Cigarette smoke; Immune system; Nicotine

Indexed keywords

CIGARETTE SMOKE; NICOTINE;

ALZHEIMER DISEASE; APOPTOSIS; CELLULAR IMMUNITY; CIGARETTE SMOKING; DRUG EFFECT; HUMAN; HUMORAL IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; REVIEW; T LYMPHOCYTE;

ANIMALS; HUMANS; IMMUNE SYSTEM; INFLAMMATION; NEURODEGENERATIVE DISEASES; NICOTINE; NICOTINIC AGONISTS; SMOKING;

EID: 67549134555     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2009.67     Document Type: Review

References (116)

1. Boyle AH, Waters HF. COPD: focus on prevention: recom-menda tions of the National Lung Health Education Program. Chronic obstructive pulmonary disease. Heart Lung 2000; 29: 446-9.
2. Johnson JD, Houchens DP, Kluwe WM, Craig DK, Fisher GL. Effects of mainstream and environmental tobacco smoke on the immune system in animals and humans: a review. Crit Rev Toxicol 1990; 20: 369-95.
3. Nishikawa M. Cigarete smoke-induced acute airway impairment. Nihon Kokyuki Gakkai Zasshi 2000; 38: 347-53.
4. Obeid P, Bercy P. Effects of smoking on periodontal health: a review. Adv Ter 2000; 17: 230-7.
5. Gold R. Epidemiology of bacterial meningitis. Infect Dis Clin North Am 1999; 13: 515-25.
6. Klareskog L, Padyukov L, Alfredsson L. Smoking as a trigger for infammatory rheumatic diseases. Curr Opin Rheumatol 2007; 19: 49-54.
7. Rhodes J, Tomas GA. Smoking: good or bad for infammatory bowel disease? Gastroenterology 1994; 106: 807-10.
8. Costenbader KH, Kim DJ, Peerzada J, Lockman S, Nobles-Knight D, Petri M, et al. Cigarete smoking and the risk of systemic lupuserythematosus: a meta-analysis. Arthritis Rheum 2004; 50: 849- 57.
9. Sobczak AJ. Te efects of tobacco smoke on the homocysteine level - a risk factor of atherosclerosis. Addict Biol 2003; 8: 147-58.
10. Sethi JM, Rochester CL. Smoking and chronic obstructive pulmonary disease. Clin Chest Med 2000; 21: 67-86.
11. Ozlu T, Bulbul Y. Smoking and lung cancer. Tuberk Toraks 2005; 53: 200-9.
12. Lindell KO, Reinke LF. Nursing strategies for smoking cessation. Heart Lung 1999; 28: 295-302.
13. Birtwistle J. Te role of cigaretes and nicotine in the onset and treatment of ulcerative colitis. Postgrad Med J 1996; 72: 714-8.
14. Birrenbach T, Bocker U. Infammatory bowel disease and smoking: a review of epidemiology, pathophysiology, and thera peutic implications. Infamm Bowel Dis 2004; 10: 848-59.
15. Quik M, Bordia T, O'Leary K. Nicotinic receptors as CNS targets for Parkinson's disease. Biochem Pharmacol 2007; 74: 1224-34.
16. Park HJ, Lee PH, Ahn YW, Choi YJ, Lee G, Lee DY, et al. Neuroprotective efect of nicotine on dopaminergic neurons by anti-infammatory action. Eur J Neurosci 2007; 26: 79-89.
17. Quik M, Parameswaran N, McCallum SE, Bordia T, Bao S, McCormack A, et al. Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates. J Neuro-chem 2006; 98: 1866-75.
18. Quik M. Smoking, nicotine and Parkinson's disease. Trends Neurosci 2004; 27: 561-68.
19. Sabbagh MN, Lukas RJ, Sparks DL, Reid RT. The nicotinic acetylcholine receptor, smoking, and Alzheimer's disease. J Alzheimers Dis 2002; 4: 317-25.
20. Fratiglioni L, Wang HX. Smoking and Parkinson's and Alzheimer's disease: review of the epidemiological studies. Behav Brain Res 2000; 113: 117-20.
21. Newhouse PA, Poter A, Kelton M, Corwin J. Nicotinic treatment of Alzheimer's disease. Biol Psychiatry 2001; 49: 268-78.
22. Blanchet MR, Israel-Assayag E, Cormier Y. Inhibitory effect of nicotine on experimental hypersensitivity pneumonitis in vivo and in vitro. Am J Respir Crit Care Med 2004; 169: 903-9.
23. Mabley JG, Pacher P, Southan GJ, Salzman AL, Szabo C. Nicotine reduces the incidence of type I diabetes in mice. J Pharmacol Exp Ter 2002; 300: 876-81.
24. Sadis C, Teske G, Stokman G, Kubjak C, Claessen N, Moore F, et al. Nicotine protects kidney from renal ischemia/reperfusion injury through the cholinergic anti-infammatory pathway. PLoS ONE 2007; 2: e469.
25. McAllister-Sistilli CG, Caggiula AR, Knopf S, Rose CA, Miller AL, Donny EC. Te efects of nicotine on the immune system. Psychoneuroendocrinology 1998; 23: 175-87.
26. Sopori M. Efects of cigarete smoke on the immune system. Nat Rev Immunol 2002; 2: 372-7.
27. Middlebrook AJ, Martina C, Chang Y, Lukas RJ, DeLuca D. Efects of nicotine exposure on T cell development in fetal thymus organ culture: arrest of T cell maturation. J Immunol 2002; 169: 2915-24.
28. Nouri-Shirazi M, Tinajero R, Guinet E. Nicotine alters the biological activities of developing mouse bone marrow-derived dendritic cells (DCs). Immunol Let 2007; 109: 155-64.
29. Guinet E, Yoshida K, Nouri-Shirazi M. Nicotinic environment afects the diferentiation and functional maturation of monocytes derived dendritic cells (DCs). Immunol Let 2004; 95: 45-55.
30. Floto R, Smith KG. Te vagus nerve, macrophages, and nicotine. Lancet 2003; 361: 1069-70.
31. Wang H, Liao H, Ochani M, Justiniani M, Lin X, Yang L, et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 2004; 10: 1216-21.
32. Rubin RL, Hermanson TM, Bedrick EJ, McDonald JD, Burchiel SW, Reed MD, et al. Efect of cigarete smoke on autoimmunity in murine and human systemic lupus erythematosus. Toxicol Sci 2005; 87: 86-96.
33. Jani N, Regueiro MD. Medical therapy for ulcerative colitis. Gastroenterol Clin North Am 2002; 31: 147-66.
34. Emre M, de Decker C. Effects of cigarette smoking on motor functions in patients with multiple sclerosis. Arch Neurol 1992; 49: 1243-7.
35. Friend KB, Mernoff ST, Block P, Reeve G. Smoking rates and smoking cessation among individuals with multiple sclerosis. Disabil Rehabil 2006; 28: 1135-41.
36. Johnson GJ, Cosnes J, Mansfield JC. Review article: smoking cessation as primary therapy to modify the course of Crohn's disease. Aliment Pharmacol Ter 2005; 21: 921-31.
37. Hawkes CH. Smoking is a risk factor for multiple sclerosis: a metanalysis. Mult Scler 2007; 13: 610-5.
38. Hernan MA, Olek MJ, Ascherio A. Cigarette smoking and incidence of multiple sclerosis. Am J Epidemiol 2001; 154: 69- 74.
39. Koch M, van Harten A, Uytenboogaart M, De Keyser J. Cigarete smoking and progression in multiple sclerosis. Neurology 2007; 69: 1515-20.
40. Shi FD, Piao WH, Kuo YP, Campagnolo DI, Vollmer TL, Lukas RJ. Nicotinic atenuation of central nervous system infammation and autoimmunity. J Immunol 2009; 182: 1730-9.
41. Sopori ML, Kozak W. Immunomodulatory effects of cigarette smoke. J Neuroimmunol 1998; 83: 148-56.
42. Hamada M, Hendrick JP, Ryan GR, Kuroiwa M, Higashi H, Tanaka M, et al. Nicotine regulates DARPP-32 (dopamine- and cAMP-regulated phosphoprotein of 32 kDa) phosphorylation at multiple sites in neostriatal neurons. J Pharmacol Exp Ter 2005; 315: 872-8.
43. Neumann S, Razen M, Habermehl P, Meyer CU, Zepp F, Kirkpatrick CJ, et al. The non-neuronal cholinergic system in peripheral blood cells: efects of nicotinic and muscarinic receptor antagonists on phagocytosis, respiratory burst and migration. Life Sci 2007; 80: 2361-4.
44. Neher GH. Nicotine-induced depression of lymphocyte growth. Toxicol Appl Pharmacol 1974; 27: 253-8.
45. Menard L, Rola-Pleszczynski M. Nicotine induces T-suppressor cells: modulation by the nicotinic antagonist D-tubocurarine and myasthenic serum. Clin Immunol Immunopathol 1987; 44: 107-13.
46. Hallquist N, Hakki A, Wecker L, Friedman H, Pross S. Diferential efects of nicotine and aging on splenocyte proliferation and the production of T1- versus T2-type cytokines. Proc Soc Exp Biol Med 2000; 224: 141-6.
47. Zhang S, Petro TM. Te efect of nicotine on murine CD4 T cell responses. Int J Immunopharmacol 1996; 18: 467-78.
48. Petro TM, Schwartzbach SD, Zhang S. Smokeless tobacco and nicotine bring about excessive cytokine responses of murine memory T-cells. Int J Immunopharmacol 1999; 21: 103-14.
49. Takahashi HK, Iwagaki H, Hamano R, Yoshino T, Tanaka N, Nishibori M. Effect of nicotine on IL-18-initiated immune response in human monocytes. J Leukoc Biol 2006; 80: 1388-94.
50. Takahashi HK, Iwagaki H, Hamano R, Yoshino T, Tanaka N, Nishibori M. alpha7 Nicotinic acetylcholine receptor stimulation inhibits lipopolysaccharide-induced interleukin-18 and -12 production in monocytes. J Pharmacol Sci 2006; 102: 143-6.
51. Yoshikawa H, Kurokawa M, Ozaki N, Nara K, Atou K, Takada E, et al. Nicotine inhibits the production of proinflammatory mediators in human monocytes by suppression of I-kappaB phosphorylation and nuclear factor-kappaB transcriptional activity through nicotinic acetylcholine receptor alpha7. Clin Exp Immunol 2006; 146: 116-23.
52. Vassallo R, Tamada K, Lau JS, Kroening PR, Chen, L. Cigarete smoke extract suppresses human dendritic cell function leading to preferential induction of T-2 priming. J Immunol 2005; 175: 2684-91.
53. Aicher A, Heeschen C, Mohaupt M, Cooke JP, Zeiher AM, Dimmeler S. Nicotine strongly activates dendritic cell-mediated adaptive immunity: potential role for progression of atherosclerotic lesions. Circulation 2003; 107: 604-11.
54. Nouri-Shirazi M, Guinet E. Evidence for the immunosuppressive role of nicotine on human dendritic cell functions. Immunology 2003; 109: 365-73.
55. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of infammation. Nature 2003; 421: 384-8.
56. Matsubayashi H, Inoue A, Amano T, Seki T, Nakata Y, Sasa M, et al. Involvement of alpha7- and alpha4beta2-type postsynaptic nicotinic acetylcholine receptors in nicotine-induced excitation of dopaminergic neurons in the substantia nigra: a patch clamp and single-cell PCR study using acutely dissociated nigral neurons. Brain Res Mol Brain Res 2004; 129: 1-7.
57. Hogg N. Nicotine has suppressive efects on dendritic cell function. Immunology 2003; 109: 329-30.
58. Gao FG, Wan da F, Gu JR. Ex vivo nicotine stimulation augments the efficacy of therapeutic bone marrow-derived dendritic cell vaccination. Clin Cancer Res 2007; 13: 3706-12.
59. 2+ stores. J Pharmacol Exp Ther 2000; 293: 166-71.
60. Sopori ML, Kozak W, Savage SM, Geng Y, Soszynski D, Kluger MJ, et al. Effect of nicotine on the immune system: possible regula tion of immune responses by central and peripheral mechanisms. Psychoneuroendocrinology 1998; 23: 189-204.
61. Basta PV, Basham KB, Ross WP, Brust ME, Navarro HA. Gestational nicotine exposure alone or in combination with ethanol down-modulates offspring immune function. Int J Immuno pharmacol 2000; 22: 159-69.
62. Kalra R, Singh SP, Pena-Philippides JC, Langley RJ, Razani-Boroujerdi S, Sopori ML. Immunosuppressive and anti-infam-matory effects of nicotine administered by patch in an animal model. Clin Diagn Lab Immunol 2004; 11: 563-8.
63. Evavold BD, Sloan-Lancaster J, Allen PM. Tickling the TCR: selective T-cell functions stimulated by altered peptide ligands. Immunol Today 1993; 14: 602-9.
64. Sloan-Lancaster J, Allen PM. Significance of T-cell stimulation by altered peptide ligands in T cell biology. Curr Opin Immunol 1995; 7: 103-9.
65. Singh SP, Kalra R, Puttfarcken P, Kozak A, Tesfaigzi J, Sopori ML. Acute and chronic nicotine exposures modulate the immune system through different pathways. Toxicol Appl Pharmacol 2000; 164: 65-72.
66. Skok M, Grailhe R, Agenes F, Changeux JP. Te role of nicotinic acetylcholine receptors in lymphocyte development. J Neuro-immunol 2006; 171: 86-98.
67. Skok M, Grailhe R, Changeux JP. Nicotinic receptors regulate B lymphocyte activation and immune response. Eur J Pharmacol 2005; 517: 246-51.
68. Skok MV, Grailhe R, Agenes F, Changeux JP. Te role of nicotinic receptors in B-lymphocyte development and activation. Life Sci 2007; 80: 2334-6.
69. Fujii YX, Fujigaya H, Moriwaki Y, Misawa H, Kasahara T, Grando SA, et al. Enhanced serum antigen-specific IgG1 and proinfammatory cytokine production in nicotinic acetylcholine receptor alpha7 subunit gene knockout mice. J Neuroimmunol 2007; 189: 69-74.
70. Matta SG, Balfour DJ, Benowitz NL, Boyd RT, Buccafusco JJ, Caggiula AR, et al. Guidelines on nicotine dose selection for in vivo research. Psychopharmacology (Berl) 2007; 190: 269-319.
71. Shivji M, Burger S, Moncada CA, Clarkson AB Jr, Merali S. Efect of nicotine on lung S-adenosylmethionine and development of Pneumocystis pneumonia. J Biol Chem 2005; 280: 15219-28.
72. Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2001; 2: 577-88.
73. Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 1999; 22: 123-44.
74. Ebersbach G, Stock M, Muller J, Wenning G, Wissel J, Poewe W. Worsening of motor performance in patients with Parkinson's disease following transdermal nicotine administration. Mov Disord 1999; 14: 1011-3.
75. Clemens P, Baron JA, Cofey D, Reeves A. Te short-term efect of nicotine chewing gum in patients with Parkinson's disease. Psychopharmacology (Berl) 1995; 117: 253-6.
76. Vieregge A, Sieberer M, Jacobs H, Hagenah JM, Vieregge P. Transdermal nicotine in PD: a randomized, double-blind, placebo-controlled study. Neurology 2001; 57: 1032-5.
77. Lemay S, Chouinard S, Blanchet P, Masson H, Soland V, Beuter A, et al. Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 31-9.
78. Gorell JM, Rybicki BA, Johnson CC, Peterson EL. Smoking and Parkinson's disease: a dose-response relationship. Neurology 1999; 52: 115-9.
79. Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ. A meta-analysis of cofee drinking, cigarete smoking, and the risk of Parkinson's disease. Ann Neurol 2002; 52: 276-84.
80. Janhunen S, Ahtee L. Differential nicotinic regulation of the nigrostriatal and mesolimbic dopaminergic pathways: implications for drug development. Neurosci Biobehav Rev 2007; 31: 287- 314.
81. Pidoplichko VI, DeBiasi M, Williams JT, Dani JA. Nicotine activates and desensitizes midbrain dopamine neurons. Nature 1997; 390: 401-4.
82. Maggio R, Riva M, Vaglini F, Fornai F, Molteni R, Armogida M, et al. Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors. J Neurochem 1998; 71: 2439-46.
83. Soto-Otero R, Mendez-Alvarez E, Hermida-Ameijeiras A, Lopez-Real AM, Labandeira-Garcia JL. Effects of (-)-nicotine and (-)-cotinine on 6-hydroxydopamine-induced oxidative stress and neurotoxicity: relevance for Parkinson's disease. Biochem Pharmacol 2002; 64: 125-35.
84. Howard LA, Miksys S, Hofmann E, Mash D, Tyndale RF. Brain CYP2E1 is induced by nicotine and ethanol in rat and is higher in smokers and alcoholics. Br J Pharmacol 2003; 138: 1376-86.
85. Miksys S, Lerman C, Shields PG, Mash DC, Tyndale RF. Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology 2003; 45: 122-32.
86. Miksys S, Tyndale RF. Nicotine induces brain CYP enzymes: relevance to Parkinson's disease. J Neural Transm Suppl 2006; (70): 177-80.
87. Mann A, Miksys S, Lee A, Mash DC, Tyndale RF. Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment. Neuropharmacology 2008; 55: 1147-55.
88. Cormier A, Morin C, Zini R, Tillement JP, Lagrue G. Nicotine protects rat brain mitochondria against experimental injuries. Neuropharmacology 2003; 44: 642-52.
89. Newman MB, Arendash GW, Shytle RD, Bickford PC, Tighe T, Sanberg PR. Nicotine's oxidative and antioxidant properties in CNS. Life Sci 2002; 71: 2807-20.
90. Xie YX, Bezard E, Zhao BL. Investigating the receptor-independent neuroprotective mechanisms of nicotine in mitochondria. J Biol Chem 2005; 280: 32405-12.
91. Quik M, Kulak JM. Nicotine and nicotinic receptors; relevance to Parkinson's disease. Neurotoxicology 2002; 23: 581-94.
92. Piccioto MR, Zoli M. Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer's and Parkinson's disease. Front Biosci 2008; 13: 492-504.
93. Quik M, McIntosh JM. Striatal alpha6* nicotinic acetylcholine receptors: potential targets for Parkinson's disease therapy. J Pharmacol Exp Ter 2006; 316: 481-9.
94. Ryan RE, Ross SA, Drago J, Loiacono RE. Dose-related neuroprotective efects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice. Br J Pharmacol 2001; 132: 1650-6.
95. Perez XA, Bordia T, McIntosh JM, Grady SR, Quik M. Long-term nicotine treatment differentially regulates striatal alpha6alpha4beta2* and alpha6(nonalpha4)beta2* nAChR expression and function. Mol Pharmacol 2008; 74: 844-53.
96. Takeuchi H, Yanagida T, Inden M, Takata K, Kitamura Y, Yamakawa K, et al. Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson's disease models. J Neurosci Res 2009; 87: 576-85.
97. Xiao Y, Fan H. Musachio JL, Wei ZL, Chellappan SK, Kozikowski AP, et al. Sazetidine-A, a novel ligand that desensitizes alpha4beta2 nicotinic acetylcholine receptors without activating them. Mol Pharmacol 2006; 70: 1454-60.
98. Shytle RD, Mori T, Townsend K, Vendrame M, Sun N, Zeng J, et al. Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors. J Neurochem 2004; 89: 337-43.
99. Khwaja M, McCormack A, McIntosh JM, Di Monte DA, Quik M. Nicotine partially protects against paraquat-induced nigrostriatal damage in mice; link to alpha6beta2* nAChRs. J Neurochem 2007; 100: 180-90.
100. Exley R, Cragg SJ. Presynaptic nicotinic receptors: a dynamic and diverse cholinergic flter of striatal dopamine neurotransmission. Br J Pharmacol 2008; 153 Suppl 1: S283-97.
101. Fedele E, Varnier G, Ansaldo MA, Raiteri M. Nicotine administration stimulates the in vivo N-methyl-D-aspartate receptor/ nitric oxide/cyclic GMP pathway in rat hippocampus through glutamate release. Br J Pharmacol 1998; 125: 1042-8.
102. Garrido R, Matson MP, Hennig B, Toborek M. Nicotine protects against arachidonic-acid-induced caspase activation, cytochrome c release and apoptosis of cultured spinal cord neurons. J Neuro-chem 2001; 76: 1395-403.
103. Toborek M, Garrido R, Malecki A, Kaiser S, Mattson MP, Hennig B, et al. Nicotine attenuates arachidonic acid-induced over expression of nitric oxide synthase in cultured spinal cord neurons. Exp Neurol 2000; 161: 609-20.
104. Mai H, May WS, Gao F, Jin Z, Deng X. A functional role for nicotine in Bcl2 phosphorylation and suppression of apoptosis. J Biol Chem 2003; 278: 1886-91.
105. Orr CF, Rowe DB, Halliday GM. An inflammatory review of Parkinson's disease. Prog Neurobiol 2002; 68: 325-40.
106. Roceri M, Molteni R, Fumagalli F, Racagni G, Gennarelli M, Corsini G, et al. Stimulatory role of dopamine on fibroblast growth factor-2 expression in rat striatum. J Neurochem 2001; 76: 990-7.
107. +-induced neurotoxicity along with brain-derived neurotrophic factor induction. J Neurochem 2001; 76: 351-60.
108. Heininger K. A unifying hypothesis of Alzheimer's disease. IV. Causation and sequence of events. Rev Neurosci 2000; 11 Spec No: 213-28.
109. Selkoe DJ. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 1999; 399: A23-31.
110. Yankner BA. New clues to Alzheimer's disease: unraveling the roles of amyloid and tau. Nat Med 1996; 2: 850-2.
111. Almeida OP, Hulse GK, Lawrence D, Flicker L. Smoking as a risk factor for Alzheimer's disease: contrasting evidence from a systematic review of case-control and cohort studies. Addiction 2002; 97: 15-28.
112. Ott A, Slooter AJ, Hofman A, van Harskamp F, Witteman JC, Van Broeckhoven C, et al. Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Roterdam Study. Lancet 1998; 351: 1840-3.
113. Utsuki T, Shoaib M, Holloway HW, Ingram DK, Wallace WC, Haroutunian V, et al. Nicotine lowers the secretion of the Alzheimer's amyloid beta-protein precursor that contains amyloid beta-peptide in rat. J Alzheimers Dis 2002; 4: 405-15.
114. Liu Q, Zhang J, Zhu H, Qin C, Chen Q, Zhao B. Dissecting the signaling pathway of nicotine-mediated neuroprotection in a mouse Alzheimer disease model. Faseb J 2007; 21: 61-73.
115. McFarlin DE, McFarland HF. Multiple sclerosis (first of two parts). N Engl J Med 1982; 307: 1183-8.
116. McFarlin DE, McFarland HF. Multiple sclerosis (second of two parts). N Engl J Med 1982; 307: 1246-51.